Sun Pharma buys controls of Taro
This article was originally published in The Tan Sheet
The Indian firm acquires a majority stake in Taro Pharmaceutical Industries for $144 million - substantially less than its initial offer of $434 million for 100 percent of the firm three years ago. Sun Chairman and Managing Director Dilip Shanghvi takes over as chairman of Taro, which distributes primarily in Israel, Canada and the U.S. Taro's reported net sales reached $360.5 million in 2009. Sun has 48.7 percent economic interest in Taro and 65.8 percent voting rights on management decisions. Taro owner Barrie Levitt maintains a 12 percent stake, but has 41 percent voting rights. Sun Director Sudhir Valia is vice chair of Taro, and his son, Aalok Shanghvi, and Sun Director Hasmukh Shah were appointed directors. FDA has approved Taro private label equivalents of branded OTCs including McNeil Consumer Healthcare's Zyrtec allergy drug (1"The Tan Sheet" Aug. 10, 2009, In Brief)
You may also be interested in...
FDA approves the Hawthorne, N.Y.-based company's abbreviated new drug application for 5-mg and 10-mg cetirizine hydrochloride tablets. Taro Pharmaceuticals said July 27 it previously received approval for an equivalent of Johnson & Johnson/McNeil's Children's Zyrtec Oral Solution (1"The Tan Sheet" April 28, 2008, In Brief). FDA has already approved private-label versions of the OTC allergy drug manufactured by Perrigo, Sandoz, Ranbaxy and Mylan
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.